Új immunterápiás lehetõségek az emlõrák kezelésében

Translated title of the contribution: Immunotherapy opportunities in breast cancer

Lajos Pusztai, A. Ladányi, Borbála Székely, Magdolna Dank

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

The prognostic value of tumor infiltrating lymphocytes in breast cancer has long been recognized by histopathologists. These observations were reaffirmed by recent immunohistochemistry and gene expression profiling studies that also revealed an association between greater chemotherapy sensitivity and extensive lymphocytic infiltration in early stage breast cancers treated with neoadjuvant chemotherapy. These results suggest that local anti-tumor immune response can at least partially control cancer growth and may mediate the antitumor effects of chemotherapy. However, until recently, there was no direct clinical evidence to demonstrate that enhancing anti-tumor immune response could lead to clinical benefit in breast cancer patients. The recent development of clinically effective immune checkpoint inhibitors made it possible to test the therapeutic impact of augmenting the local anti-tumor immune response. Two Phase I clinical trials using single agent anti-PD-1 (MK-3475, pembrolizumab) and anti-PD-L1 (MPDL3280A, atezolizumab) antibodies demonstrated close to 20% tumor response rates in heavily pretreated, metastatic, triple negative breast cancers. The most remarkable feature of the responses was their long duration. Several patients had disease control close to a year, or longer, which has not previously been seen with chemotherapy regimens in this patient population. A large number of clinical trials are currently underway with these and similar drugs in the neoadjuvant, adjuvant and metastatic settings to define the role of this new treatment modality in breast cancer.

Translated title of the contributionImmunotherapy opportunities in breast cancer
Original languageHungarian
Pages (from-to)34-40
Number of pages7
JournalMagyar Onkologia
Volume60
Issue number1
Publication statusPublished - Mar 2 2016

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Immunotherapy opportunities in breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Pusztai, L., Ladányi, A., Székely, B., & Dank, M. (2016). Új immunterápiás lehetõségek az emlõrák kezelésében. Magyar Onkologia, 60(1), 34-40.